QA: Corvus Pharmaceuticals Inc in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001626971_2023_Corvus_Pharmaceuticals_Inc.pdf

Logs

warning Missing logo subcommand.report {}

Graph

Absolute values for 0001626971, Corvus Pharmaceuticals Inc

  xvar xval
0 AssetsCurrent 43,664,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 353,000
3 remainder_Assets 24,223,000
4 LiabilitiesCurrent 10,752,000
5 LiabilitiesNoncurrent 1,373,000
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 7,469,281
9 ResearchAndDevelopmentExpense 22,263,322
10 remainder_Expenses 0
11 remainder_Revenues 0
12 remainder_NetIncome -7,467,880
13 remainder_ComprehensiveNetIncome 1,863,210
  yvar yval
0 Assets 68,240,000
1 Liabilities 12,125,000
2 Expenses 29,732,603
3 Revenues 0
4 StockholdersEquity 56,115,000
5 NetIncome -37,200,483
6 ComprehensiveNetIncome -36,268,878
7 BaseVar 59,714,346
8 EconomicCapitalRatiobeforeLimitedLiability 2.14
9 EconomicCapitalRatio 3.12

Edgar->Model Mapping

Feature Distribution

Change over Time